- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00520091
Irinotecan, Cisplatin, and Radiation Therapy With or Without Celecoxib in Treating Patients With Stage II, Stage III, or Stage IV Esophageal Cancer
A Pilot Study of the Biologic Efficacy and Safety of the Addition of Celecoxib to a Program of Induction Chemotherapy and Neo-Adjuvant Chemo-Radiotherapy for the Treatment of Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy and radiation therapy together with celecoxib may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving irinotecan and cisplatin together with radiation therapy with or without celecoxib works in treating patients with stage II, stage III, or stage IV esophageal cancer.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
OBJECTIVES:
Primary
- To measure the rates of cellular apoptosis and proliferation at baseline and during chemoradiotherapy with and without celecoxib using biopsy samples from patients with stage II, III, or IV esophageal cancer.
- To determine if an acceptable rate of pathologic complete remission can be achieved in a subset of patients with potentially resectable esophageal cancer.
Secondary
- To assess the safety of the addition of daily celecoxib to chemoradiotherapy.
- To estimate the median overall survival in a subset of patients with resectable disease.
- To quantitate expression of cyclooxygenase (COX)-2 and formation of prostaglandin E2 (PGE2) in patients with esophageal cancer.
- To assess the ability of celecoxib to decrease formation of PGE2 in tumor tissue by measuring pre- and post-treatment tumor concentrations of PGE2.
- To quantitate downstream effects of inhibition of COX-2 function in the setting of treatment with chemotherapy.
- To measure the radiographic response rate in patients with unresectable esophageal cancer.
OUTLINE: This is a multicenter study. Patients are sequentially enrolled into 1 of 2 treatment groups.
- Group 1: Patients receive cisplatin IV over 1 hour and irinotecan hydrochloride IV over 90 minutes on days 1, 8, 22, 29, 43, 50, 64, and 71. Patients also undergo radiotherapy once daily 5 days a week for 5 weeks beginning on day 43.
- Group 2: Patients receive chemoradiotherapy as in group 1. Patients also receive oral celecoxib twice daily beginning 3 days before the initiation of chemotherapy and continuing until the completion of chemoradiotherapy.
In both groups, patients with potentially resectable disease undergo surgery no more than 12 weeks after completion of chemoradiotherapy.
Endoscopic tumor biopsy specimens are collected at baseline and on day 3 of radiotherapy. Samples are analyzed for cyclooxygenase (COX)-2 gene and protein expression; PGE2 secretion; apoptotic activity; caspase-3 activation; cytochrome c translocation; VEGF mRNA quantitation; and cellular proliferation. Laboratory techniques used include RT-PCR, IHC, enzyme immunoassay, TUNEL assay, colorimetric assay, and northern blotting.
After completion of study treatment, patients are followed every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 34 patients (8-10 in group 1 and 24 in group 2) will be accrued for this study.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
DISEASE CHARACTERISTICS:
Biopsy proven squamous cell carcinoma or adenocarcinoma of the esophagus
- Lesions including the gastroesophageal junction allowed provided the tumor involves less than 2 cm of gastric cardia
Meets 1 of the following criteria:
Clinical stage II, III, or IV disease AND planning to receive chemoradiotherapy either for preoperative or palliative indications (group 1)
- Suitable candidate for bimodality (palliative intent) or trimodality (curative intent) therapy
Clinical stage II or III disease AND candidate to receive chemoradiotherapy for preoperative indication followed by planned esophagectomy or esophagogastrectomy (group 2)
- Suitable candidate for trimodality (curative intent) therapy
- No tracheoesophageal fistula on bronchoscopy
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy > 3 months (group 1)
- Not pregnant
- Adequate nutrition
- WBC ≥ 4,000/μL
- ANC ≥ 1,500/μL
- Platelet count ≥ 100,000/μL
- Serum creatinine ≤ 1.5 mg/dL
- Bilirubin ≤ 1.5 mg/dL
No other prior or concurrent malignancy other than curatively treated carcinoma in situ of the cervix; localized prostate cancer that was previously treated with local therapy more than 2 years ago with a PSA of less than 4 ng/mL; basal cell carcinoma of the skin; or superficial transitional cell carcinoma of the bladder
- Patients who have had a prior malignancy are eligible if they have been free of disease for ≥ 5 years
- No serious medical or psychiatric illnesses that would preclude giving informed consent or otherwise limit survival to less than 2 years
- No history of known NSAID-induced gastrointestinal bleeding
- No current peptic ulcer disease
- No active coronary artery disease
- No myocardial infarction or cerebrovascular accident within the past 3 months
- No history of refractory congestive heart failure or cardiomyopathy
PRIOR CONCURRENT THERAPY:
- More than 1 week since prior major surgery (group 1)
- More than 2 weeks since prior major surgery (group 2)
- No prior chemotherapy or radiotherapy
More than 30 days since prior cyclooxygenase-2 inhibitors (selective or non-selective), including, but not limited to, any of the following:
- Acetylsalicylic acid (aspirin)
- Piroxicam
- Diclofenac
- Meloxicam
- Indomethacin
- Fenoprofen
- Sulindac
- Flurbiprofen
- Tolmetin
- Ibuprofen
- Celecoxib
- Ketoprofen
- Rofecoxib
- Ketoprofen ER
- Valdecoxib
- Naproxen
- Meclofenamate
- Oxaprozin
- Mefenamic acid
- Etodolac
- Nabumetone
- Ketorolac
- No concurrent seizure medications
- No concurrent amifostine or other such agents
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Comparador Ativo: Cohort 1
Induction chemotherapy and chemoradiation without celecoxib
|
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Outros nomes:
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Outros nomes:
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
|
Experimental: Cohort 2
Induction chemotherapy and chemoradiation with celecoxib
|
65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
Outros nomes:
Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
Outros nomes:
4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Rates of cellular apoptosis and proliferation
Prazo: 5 weeks
|
Measure the rates of cellular apoptotis and proliferation in esophageal cancers from biopsy samples pre-study and during chemoradiation with and without celecoxib therapy
|
5 weeks
|
Rate of pathologic complete remission in patients with resectable disease
Prazo: 4 years
|
To determine if an acceptable rate of pathologic complete remissions can be achieved in a cohort of patients with potentially resectable esophageal carcinoma
|
4 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Number of subjects experiencing adverse events
Prazo: 30 days post radiation
|
Adverse events/toxicity will graded per the CTCAE criteria
|
30 days post radiation
|
Median overall survival of patients with resectable disease
Prazo: 4 years
|
Follow up for survival will occur at 3 month intervals during the first two years, then every 6 months during years 3 and 4.
|
4 years
|
Formation of prostaglandin E2 (PGE2) in tumor tissue
Prazo: 12 weeks
|
The ability of celecoxib to decrease formation of prostaglandin E2 (PGE2) in tumor tissue will be analyzed using a Wilcoxon signed rank test on the difference (log scale) of the pre- and post-treatment tumor concentrations of PGE2
|
12 weeks
|
Downstream effects of inhibition of cyclooxygenase 2 function
Prazo: 12 weeks
|
A difference in location of the mRNA expression of the two cohorts will be tested for using the Wilcoxon rank sum test.
A difference in the immunohistochemistry staining of the two cohorts will be tested for using polytomous logistic regression
|
12 weeks
|
Response Rate
Prazo: 4 years
|
Radiographic repsonse will be measured using RECIST critera in patients with unresectable esophageal cancer.
|
4 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Bert H. O'Neil, MD, UNC Lineberger Comprehensive Cancer Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias
- Neoplasias por local
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Neoplasias de Cabeça e Pescoço
- Doenças Esofágicas
- Neoplasias Esofágicas
- Efeitos Fisiológicos das Drogas
- Mecanismos Moleculares de Ação Farmacológica
- Agentes do Sistema Nervoso Periférico
- Inibidores Enzimáticos
- Analgésicos
- Agentes do Sistema Sensorial
- Agentes anti-inflamatórios não esteróides
- Analgésicos, Não Narcóticos
- Antiinflamatórios
- Agentes Antirreumáticos
- Inibidores da Ciclooxigenase
- Agentes Antineoplásicos
- Inibidores da Topoisomerase
- Inibidores da Ciclooxigenase 2
- Inibidores da Topoisomerase I
- Celecoxibe
- Irinotecano
Outros números de identificação do estudo
- LCCC 0203
- CDR0000561610 (Outro identificador: NCI PDQ identifier)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer de esôfago
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em CPT- 11
-
Daiichi Sankyo Co., Ltd.ConcluídoCâncer Colorretal MetastáticoJapão
-
Kazuhiko YoshimatsuHuman Genome Center, Institute of Medical Science, University of TokyoConcluídoCâncer colorretalJapão
-
University of California, San FranciscoConcluídoGlioblastoma | Gliossarcoma | Astrocitoma Anaplásico | Oligodendroglioma anaplásicoEstados Unidos
-
Icahn School of Medicine at Mount SinaiRecrutamentoTranstorno Depressivo MaiorEstados Unidos
-
JenKem Technology Co., Ltd.Concluído
-
National Cancer Institute (NCI)ConcluídoNeoplasia Sólida Maligna Refratária | Pineoblastoma | Neoplasia Sólida Maligna Recorrente | Meduloblastoma recorrente | Neuroblastoma recorrente | Rabdomiossarcoma recorrente | Meduloblastoma refratário | Neuroblastoma refratário | Rabdomiossarcoma Refratário | Tumor embrionário do sistema nervoso central... e outras condiçõesEstados Unidos, Canadá
-
Assiut UniversityAtivo, não recrutando
-
National Cancer Institute (NCI)Ativo, não recrutandoNeoplasia sólida adultaEstados Unidos
-
Grupo Hospital de MadridConcluído
-
National Cancer Institute (NCI)Ativo, não recrutandoLinfoma de Hodgkin | Linfoma Não-Hodgkin | Neoplasia Sólida Maligna Avançada | Câncer de pâncreas estágio III AJCC v6 e v7 | Câncer de pâncreas estágio IV AJCC v6 e v7 | Neoplasia Sólida Maligna Metastática | Carcinoma de Mama Triplo Negativo | Neoplasia sólida irressecável | Neoplasia Maligna Metastática e outras condiçõesEstados Unidos